The 
Introduction
Copper aspirinate is a copper complex of aspirin (see Fig. l) and has been demonstrated to be more active as an antiinflammatory agent and less irritant tom the digestive tract than aspirin [1] [2] . Moreover it has,contrary to aspirin,antiulcer activity [3] [4] . Consequently it is recommended that copper aspirinate should be clinically used to treat arthritic and other degenerative diseases. Recently we discovered that it possesses much greater efficacy than aspirin against arachidonic acid (AA) induced platelet aggregation [5] ,which suggests that copper aspirinate may be a potential antithrombotic drug. In order to explore its usage in the prevention and therapy of thromboembolic disorders related to undue 3ggregation of platelets, we have examined its antithrombotic and anticerebral ischemia activities in animal models,and report our results here. Groups of 10 ICR mice were given copper aspirinate, aspirin or the vehicle intragastrically (ig) for 7 days,and then the tail bleeding time of each group was measured using Wang's method [6] . Results [7] ,the number of mice dying in each group was recorded and the mortality calculated (Tal' 2).
Effect of copper as/ ate on cerebral ischemia injury Groups of gerils were treated with copper aspirinate or vehicle by the ig route or with nimodipine by the ip (intraperitoneal) route for 7 days just before cerebral ischemia injury was produced by occlusion of the bilateral carotid arteries followed by reperfusion. Ischemia caused by occlusion is similar to that caused by thrombosis in man. For gerbils following 20 min occlusion and one day of reperfusion,the death number of each group within 24 hours was determined,and parietotemporal cortex was dissected out for the determination of calcium and water content by means of the documented method in the literature [8] . For gerbils following 10min occlusion and 7 day reperfusion, the density of neurons in the hippocamus CA1 sector, in terms of the number of intact neurons in two fields vision,was determined under a photomicroscope according to a known method [9] . The results were presented in Tables 3,4 Table 3 show that the group of gerbils treated with copper aspirinate prior to ischemia had a greater survival than the vehicle-treated group,while there was no significant difference in mortality between groups of copper aspirinate and nimodipine,mortality being 7% and 6%,respectively. From changes in the brain calcium content during ischemia and reperfusion (see Table 4 It has been shown in our previous studies [4] that copper aspirinate significantly increases PGIzin plasma while inhibiting synthesis of TXAz,in constrast to aspirin which can only decrease the formation of TXA=and to nimodipine which acts as a vasodilator. PGIz is known to be a powerful vasodilator. So, copper aspirinate is expected to exhibit both effect of aspirin as an antiplatelet drug and of nimodipine as a vasodilator. Therefore copper aspirinate will become a more effective drug in preventing and treating thrombotic diseases, particularly cerebral ischemia companied hy abnormalities of platelet aggregation.
